MedTrace Logo

Treosulfan-based Conditioning for Transplantation in AML/MDS

NCT00491634 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-12-02

No results posted yet for this study

Summary

The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with AML and MDS not eligible for standard transplantation.

Conditions

Interventions

DRUG

treosulfan

12 g/m2 x 3 days

DRUG

Treosulfan

12 g/m2 x 3

Sponsors & Collaborators

  • Dr. Avichai Shimoni MD

    lead OTHER_GOV

Principal Investigators

  • Arnon Nagler, MD · Chaim Sheba Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491634 on ClinicalTrials.gov